Evidence map›Paper›PMID 39939513›Full record

ArticleClinical rheumatology2025

Salvage treatment of AOSD-associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy.

Ying Xu, Yufeng Yin, Wenting Li, Jin Zhou, Yan Wang, Yan Huang, TianDan Xiang, Wei Sun, Chuancai Xu, Xiaoping Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying XuDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China.ORCID http://orcid.org/0009-0004-9749-0006
Yufeng YinDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Soochow University, No. 188 Shizi St, Suzhou, 215006, China.
Wenting LiDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China.
Jin ZhouNational Clinical Research Centre for Haematologic Diseases, Jiangsu Institute of Haematology, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China.
Yan WangDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China.
Yan HuangDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China.
TianDan XiangDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China.
Wei SunDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China. 20563470@qq.com.
Chuancai XuDepartment of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China. jasonxucc@163.com.
Xiaoping HuangDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, No. 188, Shizi Street, Suzhou, 215006, China. grehxp@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAdult-onset Still's disease (AOSD)-associated macrophage activation syndrome (MAS) is a highly inflammatory condition. Currently, the main treatment method for AOSD-associated MAS is high-dose glucocorticoid shock therapy, but the effect is not satisfactory, and new therapeutic methods or drugs are urgently needed. The aim of this study was to evaluate the efficacy and safety of salvage baricitinib therapy for AOSD-associated MAS following conventional immunosuppressive therapy.

methodData from nine patients with MAS treated in the Department of Infection and the Department of Rheumatology, First Affiliated Hospital of Soochow University, from January 2020 to December 2022, were retrospective analysed. Salvage therapy with baricitinib was administered, with an initial dose of 8 mg/day. The patients' clinical symptoms and MAS indices (blood counts and triglyceride, fibrinogen, lactate dehydrogenase, sCD25, and Fer levels) were observed. After a complete response was achieved, the baricitinib dose was gradually reduced to 2-4 mg/day and maintained.

resultsThe MAS blood test results of all nine patients improved to varying degrees within 1 week post-treatment. The MAS indices gradually returned to normal approximately 8 weeks after discharge; at the 12-month outpatient follow-up, seven patients did not develop MAS again, but two patients (patients 5 and 9) had MAS recurrence. The follow-up period ended with salvage treatment with emapalumab.

conclusionsBaricitinib can effectively inhibit the inflammatory response and improve outcomes in the treatment of MAS secondary to rheumatic immunity-related diseases; moreover, this drug treatment is safe. Our study provides a new strategy for MAS salvage therapy. Key Points • Bariticinib may be a palliative treatment option for recurrent/refractory MAS.

Indexed as

AzetidinesImmunosuppressive AgentsMacrophage Activation SyndromePurinesPyrazolesSalvage TherapyStill's Disease, Adult-OnsetSulfonamidesAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultAzetidinesbaricitinibImmunosuppressive AgentsPurinesPyrazolesSulfonamidesAdult-onset Still’s diseaseBaricitinibCompassionate therapyHLHMacrophage activation syndrome

Identifiers

PMID39939513

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.